{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:20:37Z","timestamp":1793892037379,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044878"],"award-info":[{"award-number":["R01 DA044878"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044878"],"award-info":[{"award-number":["R01 DA044878"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["5K12HS026396-03"],"award-info":[{"award-number":["5K12HS026396-03"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Syringe services programs (SSPs) hold promise for providing buprenorphine treatment access to people with opioid use disorder (OUD) who are reluctant to seek care elsewhere. In 2017, the New York City Department of Health and Mental Hygiene (DOHMH) provided funding and technical assistance to nine SSPs to develop \u201clow-threshold\u201d buprenorphine services as part of a multipronged initiative to lower opioid-related overdose rates. The aim of this study was to identify barriers to and facilitators of implementing SSP-based buprenorphine services.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted 26 semi-structured qualitative interviews from April 2019 to November 2019 at eight SSPs in NYC that received funding and technical assistance from DOHMH. Interviews were conducted with three categories of staff: leadership (i.e., buprenorphine program management or leadership, eight interviews), staff (i.e., buprenorphine coordinators or other staff, eleven interviews), and buprenorphine providers (six interviews). We identified themes related to barriers and facilitators to program implementation using thematic analysis. We make recommendations for implementation based on our findings.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Programs differed in their stage of development, location of services provided, and provider type, availability, and practices. Barriers to providing buprenorphine services at SSPs included gaps in staff knowledge and comfort communicating with participants about buprenorphine, difficulty hiring buprenorphine providers, managing tension between harm reduction and traditional OUD treatment philosophies, and financial constraints. Challenges also arose from serving a population with unmet psychosocial needs. Implementation facilitators included technical assistance from DOHMH, designated buprenorphine coordinators, offering other supportive services to participants, and telehealth to bridge gaps in provider availability. Key recommendations include: (1) health departments should provide support for SSPs in training staff, building health service infrastructure and developing policies and procedures, (2) SSPs should designate a buprenorphine coordinator and ensure regular training on buprenorphine for frontline staff, and (3) buprenorphine providers should be selected or supported to use a harm reduction approach to buprenorphine treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite encountering challenges, SSPs implemented buprenorphine services outside of conventional OUD treatment settings. Our findings have implications for health departments, SSPs, and other community organizations implementing buprenorphine services. Expansion of low-threshold buprenorphine services is a promising strategy to address the opioid overdose epidemic.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00654-0","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T15:13:03Z","timestamp":1657552383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-5589","authenticated-orcid":false,"given":"Andrea","family":"Jakubowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Harocopos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czarina","family":"Navos Behrends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lopez-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,10]]},"reference":[{"key":"654_CR1","unstructured":"New York City Department of Health and Mental Hygiene. Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2019. Epi Data Br [Internet]. 2020;122. Available from: http:\/\/www1.nyc.gov\/assets\/doh\/downloads\/pdf\/epi\/datatable66.pdf"},{"key":"654_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"654_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","volume":"139","author":"EJ Edelman","year":"2014","unstructured":"Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O\u2019Connor PG, Weiss L, et al. The impact of buprenorphine\/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014;139:79\u201385.","journal-title":"Drug Alcohol Depend"},{"key":"654_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Iciar Indave B, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"issue":"3","key":"654_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O\u2019Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356\u201361.","journal-title":"J Subst Abuse Treat"},{"key":"654_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000555","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020. https:\/\/doi.org\/10.1097\/ADM.0000000000000555.","journal-title":"J Addict Med"},{"key":"654_CR7","unstructured":"National Harm Reduction Coalition. Principles of Harm Reduction [Internet]. 2020 [cited 2021 Apr 6]. Available from: https:\/\/harmreduction.org\/about-us\/principles-of-harm-reduction\/"},{"issue":"7","key":"654_CR8","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1007\/s11606-020-06409-6","volume":"36","author":"SN Kapadia","year":"2021","unstructured":"Kapadia SN, Griffin JL, Waldman J, Ziebarth NR, Schackman BR, Behrends CN. A harm reduction approach to treating opioid use disorder in an independent primary care practice: a qualitative study. J Gen Intern Med. 2021;36(7):1898\u2013905. https:\/\/doi.org\/10.1007\/s11606-020-06409-6.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"654_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/08897077.2019.1675115","volume":"41","author":"LN Pizzicato","year":"2019","unstructured":"Pizzicato LN, Johnson CC, Viner KM. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania. Subst Abuse. 2019;41(3):301\u20136. https:\/\/doi.org\/10.1080\/08897077.2019.1675115.","journal-title":"Subst Abuse"},{"issue":"1-2","key":"654_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1\u20132):23\u201335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.018.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"654_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","volume":"39","author":"MA Bachhuber","year":"2018","unstructured":"Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within prevention point Philadelphia, an urban syringe exchange program. Subst Abuse. 2018;39(2):167\u201372. https:\/\/doi.org\/10.1080\/08897077.2018.1443541.","journal-title":"Subst Abuse"},{"key":"654_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-019-0149-1","author":"J Carter","year":"2019","unstructured":"Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019. https:\/\/doi.org\/10.1186\/s13722-019-0149-1.","journal-title":"Addict Sci Clin Pract"},{"key":"654_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1635557","author":"JE Hood","year":"2019","unstructured":"Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2019. https:\/\/doi.org\/10.1080\/08897077.2019.1635557.","journal-title":"Subst Abus"},{"issue":"3","key":"654_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/10550887.2012.694603","volume":"31","author":"S Stancliff","year":"2012","unstructured":"Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278\u201387. https:\/\/doi.org\/10.1080\/10550887.2012.694603.","journal-title":"J Addict Dis"},{"issue":"1","key":"654_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/ADM.0000000000000807","volume":"16","author":"K Hill","year":"2022","unstructured":"Hill K, Nussdorf L, Mount JD, Silk R, Gross C, Sternberg D, Bijole P, Jones M, Kier R, Mccullough D, Mathur P, Kottilil S, Masur H, Kattakuzhy Sarah, Rosenthal ES. Initiation of low-threshold buprenorphine in nontreatment seeking patients with opioid use disorder engaged in hepatitis C treatment. J Addict Med. 2022;16(1):10\u20137. https:\/\/doi.org\/10.1097\/ADM.0000000000000807.","journal-title":"J Addict Med"},{"issue":"4","key":"654_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jsat.2010.12.002","volume":"40","author":"CO Cunningham","year":"2011","unstructured":"Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349\u201356.","journal-title":"J Subst Abuse Treat"},{"key":"654_CR17","unstructured":"Health Resources and Service Administration. 340B Drug Pricing Program | Official web site of the U.S. Health Resources Services Administration [Internet]. HRSA. 2021 [cited 2021 Apr 12]. Available from: https:\/\/www.hrsa.gov\/opa\/index.html"},{"issue":"SUPPL. 1","key":"654_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/QAI.0b013e31820a8226","volume":"56","author":"L Weiss","year":"2011","unstructured":"Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, et al. Integration of buprenorphine\/naloxone treatment into HIV clinical care: Lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(SUPPL. 1):68\u201375.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"654_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2149","volume":"166","author":"PT Korthuis","year":"2016","unstructured":"Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary care\u2013based models for the treatment of opioid use disorder: a scoping review. Annals Int Med. 2016;166(4):268. https:\/\/doi.org\/10.7326\/M16-2149.","journal-title":"Annals Int Med"},{"issue":"3","key":"654_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/08897077.2019.1635557","volume":"41","author":"JE Hood","year":"2020","unstructured":"Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, Glick SN, Hamblin M, Holcomb S, Mosse D, Oliphant-Wells T, Shim MHM. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from seattle, Washington. Subst Abuse. 2020;41(3):356\u201364. https:\/\/doi.org\/10.1080\/08897077.2019.1635557.","journal-title":"Subst Abuse"},{"issue":"3","key":"654_CR21","doi-asserted-by":"publisher","first-page":"e210477","DOI":"10.1001\/jamanetworkopen.2021.0477","volume":"4","author":"DR Fine","year":"2021","unstructured":"Fine DR, Lewis E, Weinstock K, Wright J, Gaeta JM, Baggett TP. Office-based addiction treatment retention and mortality among people experiencing homelessness. JAMA Network Open. 2021;4(3):e210477. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0477.","journal-title":"JAMA Network Open"},{"issue":"1","key":"654_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/003335490411900109","volume":"119","author":"D Heller","year":"2004","unstructured":"Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32\u20139. https:\/\/doi.org\/10.1177\/003335490411900109.","journal-title":"Public Health Rep"},{"issue":"2","key":"654_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1370\/afm.1239","volume":"9","author":"RM Epstein","year":"2011","unstructured":"Epstein RM, Street RL. The values and value of patient-centered care. Ann Fam Med. 2011;9(2):100\u20133.","journal-title":"Ann Fam Med"},{"key":"654_CR24","unstructured":"Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. FDA.gov. 2017. 2: 1\u20136."},{"key":"654_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-016-0538-8","author":"BF Chauhan","year":"2017","unstructured":"Chauhan BF, Jeyaraman M, Mann AS, Lys J, Skidmore B, Sibley KM, et al. Behavior change interventions and policies influencing primary healthcare professionals\u2019 practice-an overview of reviews. Implement Sci. 2017. https:\/\/doi.org\/10.1186\/s13012-016-0538-8.","journal-title":"Implement Sci"},{"key":"654_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-020-00188-5","author":"SM Murphy","year":"2020","unstructured":"Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, et al. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. Addict Sci Clin Pract. 2020. https:\/\/doi.org\/10.1186\/s13722-020-00188-5.","journal-title":"Addict Sci Clin Pract"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00654-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T15:18:36Z","timestamp":1657552716000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00654-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00654-0","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,10]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This evaluation was deemed to not be human subjects research by the Department of Health and Mental Hygiene Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}